person · Reporting owner

HALPERN JOHN D

Disclosed activity across 2 companies

Tapewire entity: 95374
SEC CIK: 0001234950

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Comera Life Sciences Holdings, Inc.CMRA · Entity 94670	Member of 10% owner group	December 27, 2023	January 08, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Comera Life Sciences Holdings, Inc.

Report date December 27, 2023 · Filed January 08, 2024

Jointly reported with Halpern Katherine H.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Trust	1,088,819	Reported balance Holding disclosure · report date 2023-12-27 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,088,819 F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2028-01-02	IndirectBy Trust	Not disclosed	Reported balance Holding disclosure · report date 2023-12-27 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2028-07-31	IndirectBy Trust	Not disclosed	Reported balance Holding disclosure · report date 2023-12-27 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2028-09-11	IndirectBy Trust	Not disclosed	Reported balance Holding disclosure · report date 2023-12-27 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2028-12-29	IndirectBy Trust	Not disclosed	Reported balance Holding disclosure · report date 2023-12-27 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.
12.0% Senior Secured Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2024-12-29	IndirectBy Trust	Not disclosed	Reported balance Holding disclosure · report date 2023-12-27 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.

Filing footnotes · ownership attribution and instrument terms

F1: Held by John D. Halpern Revocable Trust, of which both John D. Halpern and Katherine H. Halpern are trustees.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ernexa Therapeutics Inc.

Report date December 02, 2022 · Filed December 05, 2022

Section 16 reporting ended · disclosed 2022-12-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectAs trustee of family trust	450,961	Reported balance After 2022-12-02 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-12-02 · Purchase · Acquired 335,920 · Balance 450,961 F3: Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit. F1: Reflects a 1-for-20 reverse stock split effective October 17, 2022. F4: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
Warrants (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2028-12-02	IndirectAs trustee of family trust	671,840	Reported balance After 2022-12-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-12-02 · Purchase · Acquired 671,840 · Balance 671,840 F5: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation. F4: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	Direct	205	Reported balance Holding disclosure · report date 2022-12-02 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 205 F1: Reflects a 1-for-20 reverse stock split effective October 17, 2022. F2: Held by John D. Halpern

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 1-for-20 reverse stock split effective October 17, 2022.

F2: Held by John D. Halpern

F3: Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit.

F4: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

F5: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 02, 2022 Filed Dec 5, 2022 23:05 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseWarrants (Right to Purchase) · Derivative	671,840	$0.13 Strike: $3.28	$83,980.00	Disclosure SEC source: 0001062993-22-023351 · form4.xml · derivative · entry 3 HALPERN JOHN D · CIK 0001234950 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · As trustee of family trust Disclosed balance after: 671,840 Underlying: Common Stock · 671,840 shares Expires 2028-12-02 F5 · shares: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation. F5 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation. F5 · balance_after: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation. F4 · ownership.nature: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any. Read SEC document
December 02, 2022 Filed Dec 5, 2022 23:05 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseCommon Stock	335,920	$3.28	$1,101,817.60	Disclosure SEC source: 0001062993-22-023351 · form4.xml · nonDerivative · entry 2 HALPERN JOHN D · CIK 0001234950 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · As trustee of family trust Disclosed balance after: 450,961 F3 · price: Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit. F1 · balance_after: Reflects a 1-for-20 reverse stock split effective October 17, 2022. F4 · ownership.nature: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.